Date: 2017-12-05
Type of information: Research agreement
Compound: Rani Pill™ technology for the oral delivery of factor VIII (FVIII) therapy
Company: Shire (UK - USA) Rani Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: research - licensing
Action mechanism:
- drug delivery system (DDS). The Rani Pill is a capsule that delivers an intestinal injection without exposing medication to digestive enzymes. Once the capsule is consumed, it stays protected until it enters the small intestine and delivers medication into the intestinal wall. Since the intestines do not have sharp pain receptors, the intestinal delivery is expected to be pain free.
- The Rani Pill can be used for the oral delivery of large molecules, including peptides, proteins, and antibodies,
Disease: hemophilia A
Details:
- • On December 5, 2017, Shire and Rani Therapeutics, an InCube Labs company, announced a collaboration to exclusively conduct research on the use of the Rani Pill™ technology for the oral delivery of factor VIII (FVIII) therapy for patients with hemophilia A. Hemophilia causes longer-than-normal bleeding due to absent or deficient clotting factor in the blood. Those with hemophilia A are missing or deficient in FVIII, while those with hemophilia B are missing or deficient in factor IX. The aim of factor replacement therapy is for bleeding to subside when enough clotting factor has reached the source of the bleed. Currently, no oral therapies exist for the treatment of hemophilia.
- The collaboration agreement grants Shire an exclusive option to negotiate a license to develop and commercialize the technology for delivery of FVIII therapy following completion of feasibility studies. As part of the collaboration, Shire has also made an equity investment into Rani Therapeutics.
- The specific terms of this deal were not disclosed.
Financial terms:
Latest news:
Is general: Yes
